acuerdo de cres pdf. Quote. Postby Just» Tue Aug 28, am. Looking for acuerdo de cres pdf. Will be grateful for any help! Top. The inclusion of medications of the Agreement / in the POS was done to .. partially for the Commission Health Care Regulating in Colombia (CRES). Acuerdo CRES – Deroga El Acuerdo Nuevo POS. Uploaded by. Juan Marulanda · funciones binarias. Uploaded by. Juan Marulanda.
|Published (Last):||18 April 2013|
|PDF File Size:||11.16 Mb|
|ePub File Size:||13.78 Mb|
|Price:||Free* [*Free Regsitration Required]|
acuerdo 029 de 2011 cres pdf
Of the 25 patients in risk group 3, cdes Study design and sample. Am J Geriatr Pharmacother. However, despite the guidelines and the evidence of treatment benefits and safety, numerous studies have shown that a small proportion of dyslipidemic patients regularly use lipid-lowering drugs, and an even smaller percentage of people treated have serum cholesterol levels within the range recommended by international protocols Measurements of LDL-C at xe initiation were found for patients Issues and evidence for the management of dyslipidaemia in primary care.
Detection, evaluation, and treatment of high blood cholesterol in adults. A significant association was found between the rate of total-C control and the following variables: Several associated factors were also examined: The physician must make decisions and modify patient management when achieving the therapeutic goal is difficult 19, There was no statistical significance with the following variables: Models of binary logistic regression were applied using the LDL-C and triglyceride levels as the dependent variable, and variables that were significantly-associated with the dependent variable were considered covariables in the bivariate analysis.
In this study the controlled patients received doses of lovastatin that were significantly higher than those administered to the uncontrolled patients, but all patients received DDDs lower than the recommended values, as has been reported elsewhere Additionally, the rate of triglyceride control was Most patients in the present study had other risk factors that increased the difficulty of dyslipidemia management and control, especially for asymptomatic diseases, such as hypertension, diabetes, and hypothyroidism; and the use of additional medications for each of these problems results in patients with polypharmacy, as reported by another study Cholesterol control, medication adherence and illness cognition.
Quality and effectiveness of diabetes care for a group of patients in Colombia. Quality of diabetes care in U. However, with high doses of this drug, the values are quite close to the results of one study 6.
The above findings support increasing the dose of the lipid-lowering therapy based on clearly defined objectives 16, Effects of Quality Improvement Strategies for type 2 diabetes on glycemic control. It was found that the prevalence of aspirin use as a prophylaxis of cardiovascular risk was higher than that reported by other studies Subjects were predominantly female Eur J Cardiovasc Prev Rehabil.
acuerdo de cres pdf – PDF Files
Arterioscler Thromb Vasc Biol. Any incomplete record was replaced by the complete record of another randomized patient from the same city and of the same sex and age group. Information on sociodemographic and anthropometric characteristics, risk factors, and pharmacological and laboratory variables were obtained from medical records. The cost effectiveness of statin therapies in Spain inafter the introduction of generics and reference prices.
The mean doses that were used were: In this study, however, the proportion of patients who claim to have followed the correct treatment was relatively high, which is in contrast to the low rate of metabolic control Effectiveness and tolerability of ezetimibe co-administered with statins versus statin dose-doubling in high-risk patients with persistent hyperlipidemia: It has even been suggested that a suboptimal statin treatment may increase the risk of coronary events Distribution and correlates of lipids and lipoproteins in elderly Japanese-American men.
ReadCube Visualizar o texto. In Colombia, the mortality rate due to cardiovascular disease CVD ranks first among women, and second among men. The characteristics of the population analyzed are shown in Table 1. One of the authors has a contractual cred with both funding organizations, but this did not affect the content of the manuscript.
Because a lack LDL-C control occurred in patients with two or more of the following variables: Sample size calculation and power analysis: Under these circumstances, strategies aimed at identifying individuals with dyslipidemia and implementing primary and secondary CVD preventive measures have become health priorities.
Am J Manag Care.
Revised version accepted for publication on 17 December Mean differences were determined by a nonparametric test i. In the patients comprising risk group 1, None of the other three groups showed statistically-significant differences between doses of lovastatin. LDL-C measurements taken in the 6 months prior to the study were available for cases Table 3 presents the results of the bivariate analysis that compared a subgroup of patients with controlled dyslipidemia with a subgroup of patients with uncontrolled dyslipidemia belonging to risk group 1.
Statin treatment for primary prevention of vascular disease: Definition of effectiveness The effectiveness of lipid-lowering therapies was established based on the following groups, defined according to the ATP III goal set and whether it was achieved or not: From a total of 8 patients in 10 cities, a random sample of was stratified according to dyslipidemia. To determine the effectiveness of lipid-lowering therapy in a sample of patients affiliated with the Sistema General de Seguridad Social en Salud the Colombian health system.
Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: A statistically-significant association was found between the rate of dyslipidemia control and the following variables: Given that multiple studies have documented that hypercholesterolemia increases the risk of developing CVD, its control has become a goal of physicians 1.
Fitzner K, Heckinger E. To access other dyslipidemia control medications, the prescribing physician makes a special request through each Empresa Promotora de Salud health services provider, EPS to the Scientific Technical Committee CTC 11,